gemcitabine has been researched along with mesna in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Prochilo, T; Tibaldi, C | 1 |
| Kitchell, BE; Moore, AS | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
3 review(s) available for gemcitabine and mesna
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Protective Agents; Vinblastine; Vinorelbine | 2002 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Ifosfamide; Lomustine; Mesna; Neoplasms; Streptozocin; Veterinary Drugs | 2003 |
5 other study(ies) available for gemcitabine and mesna
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |